Ruth He, MD, PhD

Looking forward to our GI Oncology Summit this Friday @HMethodistMD @MethodistHosp. Regional, National and International Esteemed faculty will be discussing 🔥 topics in GI malignancy. @ASCO @curecc @myESMO @VuMediHemOnc @DAVAOnc @OncLive

@NoureddinMD chairing the the first session in our Summit....lead the discussion on 🔥 topics of hematology...AI and others!

I am thrilled to congratulate our CMO, Dr. Juan W. Valle, for being named a 2025 Clarivate Highly Cited Researcher—one of the top 1% of researchers worldwide! His work continues to advance clinical research and care for the CCA community. 💚 share.google/brBXLN8sVf6a6M…

@MaenAbdelrahim kicking off a great GI Oncology Summit @houstonmethodist. Thank you for the invitation to speak! @mayscancer @UTHealthSA

I am thrilled to celebrate Dr. Renuka Iyer’s appointment as CMO of @NCCN. She’s been an incredible partner to the CCA community through her work with CCF and her 2021 Mark R. Clements Award. We’re grateful for all she’s done and excited for what’s ahead. newswise.com/articles/renuk…

Congratulations to Dr. Iyer on becoming the new CMO of the @NCCN! Having learned so much under her guidance, I’m beyond grateful for her mentorship, kindness, and example of what true leadership looks like. A real #BossLady changing the future of cancer care. @WomenInOncology

LEVIATHAN publication Get expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for #HCC 📺 from Prof. David Pinato (@DJPinato) 🤝 Programme endorsed by @EuropeLiver, @BlueFaeryLiver, @GlobalLiver & @ESDO_tweets View/download the infographic: cor2ed.com/hcc-connect/pr… This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content. #MedEd #Oncology

⭐️We just spoke with @RuthHe12 who presented on transplant oncology for #cholangiocarcinoma and genomic-guided strategies @HMethodistMD. 🧬She provided valuable insight into the future of genomic-guided transplant oncology. Courtesy of Houston Methodist Hospital

Anwaar, congratulations! Great job!

Learn more about @LombardiCancer's @RideBellRinger event on October 24th and 25th. Join or support the Ruesch Riders team today! ride.bellringer.org/team/team/team…

⭐ In this roundtable discussion led by @RuthHe12, #GIOncology experts, like @MarkYarchoan, discuss the state of #HCC treatment, including the challenges in establishing effective perioperative strategies following the failure of #adjuvant atezo/bev: buff.ly/YuI8zUm

What role do IO and IO combinations play in the systemic treatment landscape for pts w/ unresectable HCC? What do the latest trial data say about combining IO with locoregional therapies? Get an expert overview of the expanding role of IO for HCC Med Ed video from Prof. @RuthHe12 & Prof. @BeauToskichMD AstraZeneca has provided a sponsorship grant towards this independent programme

In vivo CRISPR screens identify modifiers of CAR-T cell function in myeloma - targeting cell cycle inhibitor CDKN1B, or p27 might enhance CAR-T effectiveness. rdcu.be/eH4jL @MangusoLab @MarcelaMaus @MassGeneralNews

October is #LiverCancerAwareness Month! At ILCA, we’re sharing the facts, the stories, and the fight against liver cancer. 💬 What’s one thing you wish more people knew about liver cancer? Share your thoughts, stories, or experiences and let’s raise awareness together.

This week, we highlighted research by Narayanan Sadagopan, Hongkun Wang, @ChYin89, @benweinbergmd, @mnoel3232, @ReetuMukherjiMD Xue Geng, @marshalj23, Branden S Moriarity, and @RuthHe12 published in @Nature_NPJ- bit.ly/3GyERvj. Full search: bit.ly/4lsH6zk.

Why #Y90? At ILCA #STW25, we explored evolving strategies in #HCC & #BTCs with top experts in liver cancer. Missed the live discussion on 6 June in Chicago? 🎥Session recordings are now available at ILCA website: #STW25-recordings" target="_blank" rel="nofollow noopener">ilcalive.org/single-topic-w…

.@benweinbergmd, discussed early results from the phase 2 EXPEL PANC trial (NCT05558982), evaluating BXCL701 plus pembrolizumab (Keytruda) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) after progression on chemotherapy. onclive.com/view/five-unde… via @onclive @benweinbergmd @LombardiCancer

From palliative care a decade ago to first-line curative intent treatment today, #Y90 radiation segmentectomy has been a welcome advancement in #livercancer treatment. 🧩 pubs.rsna.org/doi/epdf/10.11… @RSNA @SIRspecialists @cirsesociety @APASLnews @JSHLiver @myESMO @BCLC_group @EASLnews

Fresh off the press! @benweinbergmd @ReetuMukherjiMD @mnoel3232 @marshalj23 @RuthHe12 , Thanks for your contribution to this project. Special thanks to Dr.Narayanan Sadagopan, our graduating fellow. nam02.safelinks.protection.outlook.com/?url=https%3A%….

Incredible news! #LR5 (Definite #HCC) criteria of #LIRADS, including #CEUS, are now fully aligned with #OPTN #liver #transplant @UNOSNews @RadiologyACR @chemshift1 optn.transplant.hrsa.gov/media/ojdh4qi1…